WPD Pharmaceuticals Board of Directors Approved the Raise of WPD Poland's Share Capital
WPD Pharmaceuticals Board of Directors Approved the Raise of WPD Poland's Share Capital
Vancouver, British Columbia--(Newsfile Corp. - September 20, 2022) - WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the "Company" or "WPD") a clinical-stage pharmaceutical company announces that the Company's Board of Directors (the "Board") has approved the raise of WPD Pharmaceuticals Sp. z o.o. ("WPD Poland"), the Polish subsidiary of the Company share capital from PLN 400,000 to PLN 2,100,000, that is by the amount of PLN 1,700,000, by establishment of 34,000 new, equal and indivisible shares of the nominal value of PLN 50 each and the total nominal value of PLN 1,700,000. Raise of WPD Poland's share capital is the second step of a plan to restructure WPD Poland, which the company announced on February 9, 2022.
温哥华，不列颠哥伦比亚省-(Newsfile Corp.-2022年9月20日)-WPD制药公司公司(CSE：WBIO)(FSE：8SV1)(The“公司”或“WPD”)一家临床阶段的制药公司宣布，公司董事会(“董事会”)已批准WPD PharmPharmticals Sp.ZO.O。(“WPD波兰”)，公司的波兰子公司通过设立34,000股新的、平等和不可分割的股份，将股本从400,000兹罗提增加到2,100,000兹罗提，即1,700,000兹罗提，每股面值50兹罗提，总面值1,700,000兹罗提。WPD波兰公司2022年2月9日宣布的重组计划的第二步是筹集WPD波兰的股本。
According to the above on September 14, 2022, WPD Poland's Shareholders' Meeting has approved a share capital from PLN 400,000 to PLN 2,100,000. The new shares will be subscribed and taken-up by biotech investor by December 31, 2022. The long-term plans of the company include obtaining capital from the Polish capital market and listing of WPD Polska on the Warsaw Stock Exchange. The implementation of this plan depends on developments in the capital market in Europe.
如上所述，2022年9月14日，WPD波兰公司的股东大会批准了从40万兹罗提到210万兹罗提的股本。新股将于2022年12月31日前由生物技术投资者认购和认购。该公司的长期计划包括从波兰资本市场获得资本，以及WPD Polska在华沙证券交易所上市。这一计划的实施取决于欧洲资本市场的发展。
About WPD Pharmaceuticals
关于WPD制药公司
WPD is a biotechnology research and development company with a focus on oncology and virology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has licensed in certain countries 9 novel drug candidates with 4 that are in clinical development stage. These drug candidates were researched at medical institutions, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.
WPD是一家生物技术研发公司，专注于肿瘤学和病毒学，即研究和开发涉及生物化合物和小分子的医药产品。WPD已经在某些国家批准了9种新药候选药物，其中4种处于临床开发阶段。这些候选药物是在医疗机构进行研究的，WPD目前正在与维克森林大学以及波兰的领先医院和学术中心进行合作。
WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things. The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes about 29 countries in Europe and Asia, including Russia, depending on the compound.
WPD与维克森林大学健康科学公司签订了许可协议，并分别与Moleclin Biotech，Inc.和CNS PharmPharmticals，Inc.签订了分许可协议，每一项协议都向WPD授予许可方的某些技术的独家、承担版税的分许可。这些协议为WPD提供了某些研究、开发、制造和销售等权利。CNS制药和Moleclin Biotech的再许可领域包括欧洲和亚洲的大约29个国家，包括俄罗斯，具体取决于化合物。
On Behalf of the Board
我谨代表董事会
'Mariusz Olejniczak'
‘Mariusz OlejNiczak’
Mariusz Olejniczak
CEO, WDP Pharmaceuticals
马里乌兹·奥列尼扎克
WDP制药公司首席执行官
Contact:
联系方式：
Investor Relations
Email: investors@wpdpharmaceuticals.com
Tel: 604-428-7050
投资者关系
电子邮件：Investors@wpdPharmPharmticals.com
电话：604-428-7050
Web:
网页：
Cautionary Statements:
警示声明：
Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.
加拿大证券交易所和加拿大投资行业监管组织均不对本新闻稿的充分性或准确性承担责任。
This press release contains forward-looking statements. Forward-looking statements are statements that contemplate activities, events or developments that the Company anticipates will or may occur in the future, that WPD would significantly benefit from advancement of Berubicin as a treatment for GBM. Forward-looking statements in this press release include that WPD's drugs could be developed into novel treatments for cancer. These forward-looking statements reflect the Company's current expectations based on information currently available to management and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those projected. Factors which may prevent the forward looking statement from being realized is that the drug compounds may not provide the benefits expected and we may not develop them further; competitors or others may successfully challenge a granted patent and the patent could be rendered void; that we are unable to raise sufficient funding for our research; that we may not meet the requirements to receive the grants awarded; that our drugs don't provide positive treatment, or if they do, the side effects are damaging; competitors may develop better or cheaper drugs; and we may be unable to obtain regulatory approval for any drugs we develop. The Company assumes no obligation to update them except as required by applicable law.
本新闻稿包含前瞻性陈述。前瞻性陈述是对公司预期未来将会或可能发生的活动、事件或发展的陈述，这些活动、事件或发展将从贝鲁比星作为治疗GBM的方法的进步中显著受益。本新闻稿中的前瞻性陈述包括WPD的药物可能被开发成癌症的新疗法。这些前瞻性陈述反映了基于管理层目前掌握的信息的公司目前的预期，并受到许多风险和不确定因素的影响，这些风险和不确定因素可能会导致结果与预期的大不相同。可能阻碍前瞻性陈述实现的因素是，药物化合物可能无法提供预期的益处，我们可能无法进一步开发它们；竞争对手或其他人可能成功挑战已授予的专利，专利可能被宣布无效；我们无法为我们的研究筹集足够的资金；我们可能无法满足获得授予的赠款的要求；我们的药物不能提供积极的治疗，或者如果提供了，副作用是破坏性的；竞争对手可能会开发出更好或更便宜的药物；以及我们开发的任何药物可能无法获得监管部门的批准。除适用法律要求外，本公司不承担更新它们的义务。
To view the source version of this press release, please visit
要查看本新闻稿的源版本，请访问